【摘要】 目的：联合检测血清和胸水中细胞角蛋白１９ 片段（ＣＹＦＲＡ２１－ １）和腺苷脱氨酶（ＡＤＡ）活性，旨在探讨其对良、恶性胸水的鉴别诊断意义。方法：用免疫放射法（ＩＲＭＡ） 检测血清及胸水ＣＹＦＲＡ２１－１ 并用Ｇｉｕｓｔｉ 改良法检测ＡＤＡ活性。结果：非小细胞肺癌（ＮＳＣＬＣ） 组胸水ＣＹＦＲＡ２１－ １ 较结核组及小细胞肺癌（ＳＣＬＣ） 组明显增高（ Ｐ＜ ０．０１）；ＮＳＣＬＣ组胸水ＣＹＦＲＡ２１－ １ 较血清ＣＹＦＲＡ２１－ １ 亦明显增高（ Ｐ＜ ０．０１）；结核组ＡＤＡ胸水／血清比值（ＡＤＡｐ／ｓ） 较肺癌组显著增高（ Ｐ＜０ ．０１）。联合检测胸水ＣＹＦＲＡ２１ －１ 及ＡＤＡｐ／ｓ 对肺癌诊断的敏感性为１００％ ，特异性为８３％ ，准确率为９１ ％ 。结论：联合检测胸水和血清ＣＹＦＲＡ２１ －１ 及ＡＤＡ活性对良、恶性胸水鉴别诊断有一定价值。更多还原

【Abstract】 Objective:To measure CYFRA 21-1 levels and adenosine deaminase activity in serum and pleural fluid.To aim at investigating the roles in differentiation diagnosis of benign and malignant pleural fluid.Method:To measure CYFRA 21-1 levels in serum and pleural fluid by IRMA,and to measure adenosine deaminase activity in serum and pleural fluid by the modified Ginsti assays.Result:CYFRA 21-1 levels of non small lung cancer (NSCLC) group were higher than those of tuberculosis group and small cell lung cancer (SCLC) group in pleural fluid (P<0.01);CYFRA 21-1 level of pleural fluid was higher than that of serum in NSCLC group;The ration of pleural fluid to serum for ADA(ADAp/s) in tuberculosis group were higher than that in lung cancer group (P<0.01).If CYFRA 21-1 levels and ADAp/s in pleural fluid were measured simultaneously for differentiation diagnosis of lung cancer,the sensitivity rates were 100%,the speciticity rates were 83%,the accuracy rates were 91%.Conclusion:It had potential value to measure CYFRA 21-1 levels and adenosine deaminase activity simultaneously for differentiation diagnosis of benign and malignant pleural fluid.更多还原